HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Is intralesional injection of OK-432 effective in the treatment of lymphangioma in children?

AbstractBACKGROUND:
Intralesional injection of OK-432 has been proposed as an effective treatment of lymphangioma. The aim of this study was to review our experience with OK-432 injection of lymphangioma and to identify factors associated with successful outcome.
METHODS:
We made a case note review of 19 children who received OK-432 injection. Median duration of follow-up was 17 months.
RESULTS:
Lesions were diagnosed antenatally in 4 children, at birth in 4 children, and between 1 month and 11 years in the remainder. Anatomic locations were head/neck in 14, axilla in 1, and multiple locations in 4. Median number of injections per child was 2 (range, 1 to 5). Disappearance of the lesion was achieved after OK-432 injection in 2 patients (11%) and a marked reduction in 5 (26%); all these lesions were in the head and neck. Lesions larger than 5 cm and those outside the head and neck region did not respond well to OK-432 injection. Fourteen children (74%) required surgical excision after injection. Complications of OK-432 injection included partial tracheal obstruction, fever, local inflammatory response, and abscess formation.
CONCLUSIONS:
OK-432 injection was effective in approximately one third of children with lymphangioma. Lesions outside the head and neck and those larger than 5 cm are unlikely to respond to this therapy. Injection of lymphangioma surrounding the airways may be hazardous.
AuthorsNigel Hall, Niyi Ade-Ajayi, Clive Brewis, Derek J Roebuck, Edward M Kiely, David P Drake, Lewis Spitz, Agostino Pierro
JournalSurgery (Surgery) Vol. 133 Issue 3 Pg. 238-42 (Mar 2003) ISSN: 0039-6060 [Print] United States
PMID12660633 (Publication Type: Journal Article)
Chemical References
  • Antineoplastic Agents
  • Picibanil
Topics
  • Antineoplastic Agents (administration & dosage)
  • Child
  • Child, Preschool
  • Female
  • Follow-Up Studies
  • Humans
  • Infant
  • Infant, Newborn
  • Injections, Intralesional
  • Lymphangioma (drug therapy, surgery)
  • Male
  • Picibanil (administration & dosage)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: